Considering the clinical implications of significantly reduced HTLV-1 proviral load and CSF neopterin and CXCL10 levels in this study, a future study using real-world data as a control is expected to investigate the long-term efficacy of mogamulizumab in suppressing HAM/TSP disease progression. This evidence concerns the gene CXCL10 and tropical spastic paraparesis.